Although it is widely agreed that ER expression monotonically decreases the risk of clinical prognosis for breast cancer patients, the ideal clinically meaningful cutoff value for ER expression for various clinical endpoints is still not well understood. This evidence concerns the gene ESR1 and breast carcinoma.